Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 100
Updated:6/20/2018
Start Date:August 2016
End Date:December 2021
Contact:Rajani Sebastian, PhD, CCC-SLP
Email:rsebast3@jhmi.edu
Phone:410-502-6045

Use our guide to learn which trials are right for you!

Cerebellar Transcranial Direct Current Stimulation to Augment Chronic Aphasia Treatment

People with post-stroke aphasia are left with some degree of chronic deficit for which
current rehabilitative treatments are variably effective. This study investigates the
behavioral and neural effects of multiple consecutive cerebellar tDCS sessions coupled with
computerized naming therapy in stroke survivors with aphasia.

The investigators will study the effect of right cerebellar transcranial direct current
stimulation (tDCS) stimulation during language therapy for naming in individuals with chronic
aphasia (>6 months post stroke). Naming difficulties are a persistent and common symptom in
aphasia after left-hemisphere (LH) stroke. Although the interventions to improve naming can
have benefits, a massive number of treatment sessions is usually required to show gains,
particularly in individuals with chronic, large LH stroke. tDCS is a promising adjunct to
traditional language therapy. tDCS is a safe, non-invasive, non-painful electrical
stimulation of the brain which modulates cortical excitability by application of weak
electrical currents in the form of direct current brain polarization. It is usually
administered via saline-soaked surface sponge electrodes attached to the scalp and connected
to a direct current stimulator with low intensities. Prior investigators have mainly focused
on the role of LH in language recovery, wherein the electrode is placed in the left frontal
or temporal region. However, in individuals with large lesions involving key language areas
like the frontal and temporal cortex, it may be difficult to find viable tissue to stimulate
in the LH. This study uses a novel electrode placement for chronic stroke patients with
aphasia with large LH lesions. Targeting the intact right cerebellum allows for the
possibility of identifying a single target that can be used across groups of people with
aphasia with varying lesion sites and size in the LH. Evidence from functional neuroimaging
and clinical studies indicate that the right cerebellum is important for both language and
cognitive functions.

The investigators will utilize a randomized, double-blind, sham controlled, within-subject
crossover trial design. A random subset (half) of participants will be assigned to the
"anode" group (Group Anode) and other half will be assigned to the 'cathode' group (Group
Cathode). Participants will take part in 2 intervention periods of 15 computerized naming
training sessions (3-5 sessions per week), with either tDCS + naming therapy or sham+ naming
therapy, separated by 2 months. Detailed language evaluation will take place before,
immediately after, 2 weeks and 2 months post-intervention for each condition. The
investigators will test the hypothesis that anodal tDCS or cathodal tDCS over the cerebellum
and computerized naming therapy is associated with greater gains in accuracy in naming
pictures, compared to sham combined with the same computerized naming therapy.

Inclusion Criteria:

- Participants must have sustained a left hemisphere stroke.

- Participants must be fluent speakers of English by self-report.

- Participants must be capable of giving informed consent or indicating another to
provide informed consent.

- Participants must be age 18 or older.

- Participants must be premorbidly right handed.

- Participants must be at least 6 months post stroke.

- Participants must have an aphasia diagnosis as confirmed by the Boston Diagnostic
Aphasia Examination (BDAE) Short Form.

- Participants must achieve at least 65% accuracy on screening task (comparable to
treatment task) on 1 of 3 attempts

Exclusion Criteria:

- Participants with lesion involving the right cerebellum

- Previous neurological or psychiatric disease.

- Seizures during the previous 12 months.

- Uncorrected visual loss or hearing loss by self-report.

- Use of medications that lower the seizure threshold (e.g., methylphenidate,
amphetamine salts).

- Use of N-methyl-D-aspartate receptor (NMDA) antagonists (e.g., memantine).

- > 80% (140 out of 175) correct responses on the Philadelphia Naming Test at baseline.

- History of brain surgery or any metal in the head.

- Scalp sensitivity (per participant report).
We found this trial at
1
site
733 North Broadway
Baltimore, Maryland 21205
(410) 955-3182
Principal Investigator: Rajani Sebastian, PhD
Phone: 410-502-6045
Johns Hopkins University School of Medicine Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials